Contact Dermatitis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：38頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Contact Dermatitis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Contact Dermatitis - Pipeline Review, H1 2014’, provides an overview of the Contact Dermatitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Contact Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contact Dermatitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Contact Dermatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Contact Dermatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Contact Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Contact Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Contact Dermatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Contact Dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Contact Dermatitis - Pipeline Review, H1 2014’, provides an overview of the Contact Dermatitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Contact Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contact Dermatitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Contact Dermatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Contact Dermatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Contact Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Contact Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Contact Dermatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Contact Dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Contact Dermatitis Overview 6
Therapeutics Development 7
Pipeline Products for Contact Dermatitis - Overview 7
Pipeline Products for Contact Dermatitis - Comparative Analysis 8
Contact Dermatitis - Therapeutics under Development by Companies 9
Contact Dermatitis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Contact Dermatitis - Products under Development by Companies 12
Contact Dermatitis - Companies Involved in Therapeutics Development 13
R-Tech Ueno, Ltd. 13
Marinomed Biotechnologie GmbH 14
Anacor Pharmaceuticals, Inc. 15
Celsus Therapeutics Plc 16
Hapten Sciences, Inc. 17
Contact Dermatitis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
MRX-6 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RTU-1096 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MAM-06.301 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AN-3485 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
HPT-721 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Contact Dermatitis - Recent Pipeline Updates 32
Contact Dermatitis - Dormant Projects 34
Contact Dermatitis - Product Development Milestones 35
Featured News & Press Releases 35
May 08, 2013: Celsus Therapeutics Announces Positive Phase II Interim Results For MRX-6 In Treatment Of Contact Dermatitis 35
Aug 25, 2009: Morria Biopharmaceuticals Plc. Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug 36
Aug 30, 2002: Cephalon Announces Modafinil Receives Marketing Clearance In Australia, New Zealand and South Korea 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38
List of Tables
Number of Products under Development for Contact Dermatitis, H1 2014 7
Number of Products under Development for Contact Dermatitis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Contact Dermatitis - Pipeline by R-Tech Ueno, Ltd., H1 2014 13
Contact Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2014 14
Contact Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 15
Contact Dermatitis - Pipeline by Celsus Therapeutics Plc, H1 2014 16
Contact Dermatitis - Pipeline by Hapten Sciences, Inc., H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 25
Contact Dermatitis Therapeutics - Recent Pipeline Updates, H1 2014 32
Contact Dermatitis - Dormant Projects, H1 2014 34
List of Figures
Number of Products under Development for Contact Dermatitis, H1 2014 7
Number of Products under Development for Contact Dermatitis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Molecule Type, H1 2014 25
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Contact Dermatitis Overview 6
Therapeutics Development 7
Pipeline Products for Contact Dermatitis - Overview 7
Pipeline Products for Contact Dermatitis - Comparative Analysis 8
Contact Dermatitis - Therapeutics under Development by Companies 9
Contact Dermatitis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Contact Dermatitis - Products under Development by Companies 12
Contact Dermatitis - Companies Involved in Therapeutics Development 13
R-Tech Ueno, Ltd. 13
Marinomed Biotechnologie GmbH 14
Anacor Pharmaceuticals, Inc. 15
Celsus Therapeutics Plc 16
Hapten Sciences, Inc. 17
Contact Dermatitis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
MRX-6 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RTU-1096 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MAM-06.301 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AN-3485 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
HPT-721 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Contact Dermatitis - Recent Pipeline Updates 32
Contact Dermatitis - Dormant Projects 34
Contact Dermatitis - Product Development Milestones 35
Featured News & Press Releases 35
May 08, 2013: Celsus Therapeutics Announces Positive Phase II Interim Results For MRX-6 In Treatment Of Contact Dermatitis 35
Aug 25, 2009: Morria Biopharmaceuticals Plc. Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug 36
Aug 30, 2002: Cephalon Announces Modafinil Receives Marketing Clearance In Australia, New Zealand and South Korea 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38
List of Tables
Number of Products under Development for Contact Dermatitis, H1 2014 7
Number of Products under Development for Contact Dermatitis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Contact Dermatitis - Pipeline by R-Tech Ueno, Ltd., H1 2014 13
Contact Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2014 14
Contact Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 15
Contact Dermatitis - Pipeline by Celsus Therapeutics Plc, H1 2014 16
Contact Dermatitis - Pipeline by Hapten Sciences, Inc., H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 25
Contact Dermatitis Therapeutics - Recent Pipeline Updates, H1 2014 32
Contact Dermatitis - Dormant Projects, H1 2014 34
List of Figures
Number of Products under Development for Contact Dermatitis, H1 2014 7
Number of Products under Development for Contact Dermatitis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Molecule Type, H1 2014 25
